Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 6, 2024Journal of ArrhythmiaOpen Access

Meta‐analysis evaluating apixaban in patients with atrial fibrillation and end‐stage renal disease requiring dialysis

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAhmed AlTurkiMMMariam MarafiADAhmed Dawas

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

AlTurki et al. (2024) studied this question.

synapsesocial.com/papers/68e6b5efb6db643587636bfbhttps://doi.org/10.1002/joa3.13051
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and Efficacy of Apixaban versus warfarin in patients with atrial fibrillation or Venous Thromboembolism and End-Stage renal disease on hemodialysis: A systematic review and meta-analysis2021 · 8 citations
  2. 2Comparative efficacy and safety of apixaban and rivaroxaban versus warfarin in atrial fibrillation patients with end-stage renal disease: a systematic review and meta-analysis2026
  3. 3Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial2022 · 235 citations
  4. 4Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease2021 · 16 citations
  5. 5Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end‐stage kidney disease: A national cohort study2022 · 38 citations